Company intelligence / Profile preview

TRIANA Biomedicines

Lexington, Massachusetts, United Statestrianabio.com ↗

Ownership: Private
Employees: ~16
Development stage: Preclinical

Overview

TRIANA is developing a molecular glue discovery platform to identify novel therapeutics that can address previously undruggable targets. The company is currently in the discovery and pre-clinical stages.

Therapeutic areas: Oncology
Modalities: Small moleculesmolecular gluestargeted protein degraders
Industry: Biotech

Drug pipeline

5 assets

TRI-611

4 more assets in the full pipeline.

Request access →

Partnerships

Pfizer (strategic collaboration and licensing agreement announced October 15, 2024)

Beyond the preview

Go deeper on TRIANA Biomedicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRIANA Biomedicines.

Explore the full profile